COYA - Company ID 0001835022
The table below shows Coya Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $251.15K | $3.56M | $163.62K | $257.88K | $0.00 | $3.43M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Coya Therapeutics, Inc. reported annual revenue of $7.95M for fiscal year 2025. That is up 123.6% from $3.55M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.78M |
| $2.56M |
| $2.91M |
| $2.71M |
| $2.22M |
| $2.09M |
| Operating income | -$7.64M | -$2.43M | -$6.41M | -$7.68M | -$4.45M | -$3.24M |
| Income tax | - | - | $0.00 | - | - | $0.00 |
| Net income | -$7.21M | -$2.12M | -$6.09M | -$7.31M | -$4.02M | -$2.89M |
| EPS (diluted) | -$0.32 | -$0.13 | -$0.36 | -$0.44 | -$0.26 | -$0.19 |